Potential new treatments for Parkinson’s disease, developed by researchers at Rush University Medical Center, show they have been successful in slowing disease progression in mice.
In a study published in Nature CommunicationRush researchers have found that two different peptides (chains of amino acids) help slow the spread of Î±-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. Lewy body dementia is characteristic of Parkinson’s disease, the most common movement disorder affecting approximately 1.2 million people in the United States and Canada.
âCurrently, there is no cure to slow the progression of Parkinson’s disease. It only cures symptoms, âsaid Dr. Kalipada Pahan, professor of neurology and career researcher at Rush University Medical Center. Jesse Brown VA Medical Center, who led the study.
Lewy bodies are also associated with the development of a rare neuropathy called Lewy body dementia and multisystem atrophy (MSA). âCurrent and Effective Treatment In the case of Lewy body dementias and multisystem atrophy, understanding how these disorders work is effective in controlling -synuclein pathology, protecting the brain and stopping Lewy progression. It is important for the development of various drugs. sick body. “
The lab-grown peptides tested in this study are known as the TLR2 Interaction Domain (TIDM) and NEMO Binding Domain (NBD) of Myd88. The nasal medication has been shown to slow brain inflammation and stop the spread of -synuclein in mice with Parkinson’s disease. The treatment also improved gait, balance and other motor functions in mice.
âIf we can replicate these results in patients, it will be a remarkable breakthrough in the treatment of catastrophic neuropathy,â says Pahan.
This study was funded by the National Institutes of Health. The other authors of this article are Debashis Dutta, Ph.D. est. Dr MalavÃ© de Jana; Moumita Majumder, Ph.D. Susanta Mondel, Ph.D.; And Avik Roy, Ph.D., All of Rush University Medical Center.
New information on the early stages of Lewy body dementia
Selective targeting of the Debashis Dutta et al, TLR2 / MyD88 / NF-ÎºB pathway reduces the diffusion of -synuclein in vitro and in vivo. Nature Communication (2021). DOI: 10.1038 / s41467-021-25767-1
Rush University Medical Center
Quote: Nasal Medicine is a lab study obtained on September 21, 2021, from https://medicalxpress.com/news/2021-09-nasal-drugs-parkinson-disease-lab.html (September 21, 2021) Shows the potential slow down the progression of Parkinson’s disease
This document is subject to copyright. No part may be reproduced without written permission, except for fair dealing for the purposes of personal investigation or research. The content is provided for informational purposes only.
Nasal medicine has been shown in lab studies to slow the progression of Parkinson’s disease
Source link Nasal medicine has been shown in laboratory studies to slow the progression of Parkinson’s disease